Grid Therapeutics, a biotechnology company, announced the closing of its series A financing round on Thursday, according to a news release.

The company plans to use the money raised to fund the antibody production and Phase 1 clinical trials of its lead candidate for the treatment of solid tumors. The amount was undisclosed.

The series A financing was led by the Singapore-based venture capital firm Longview International Ltd. The firm frequently invests in life science companies. Duke University also became a shareholder in the company.

Durham-based Grid Therapeutics is developing the first human derived targeted immunotherapy for cancer.

In August, Grid Therapeutics announced an exclusive license agreement with Duke to develop this technology. Under this agreement, the company acquired exclusive rights to all intellectual property, including patents, related to Complement Factor H antibodies as a cancer therapy.

“Grid Therapeutics is very excited to welcome Longview to our team, especially given Longview’s active participation in companies acclaimed for innovation in biotechnology,” said Dr. Edward F. Patz, CEO of Grid Therapeutics, in a statement. “We are confident that Longview is well positioned to help Grid advance our novel antibody to the clinic.”

Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must file what’s known as a Form D electronically with the SEC after they first sell their securities.